Business

Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the

articleDianthus Therapeutics, Inc.June 8, 20205/company/dianthus-therapeutics-inc/news/magenta-therapeutics-to-participate-in-upcoming-healthcare-investor-conferences-2020
Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences

About this update from Dianthus Therapeutics, Inc.

[{"type":"text","content":" CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nMagenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced that the company will participate in a fireside chat and hold investor meetings at the 41st annual Goldman Sachs Healthcare Conference on June 11th, 2020. The Company will also hold investor meetings and participate in a panel discussion on novel approaches for gene therapy on Monday, June 15th at the Raymond James Human Health Innovation Conference.\n\n\nA live webcast of the fireside chat at the Goldman Sachs conference can be accessed on the Magenta Therapeutics website at https://investor.magentatx.com/events-and-presentations. The webcast replay will be available for 90 days following the event.\n\n\nAbout Magenta Therapeutics\n\n\nMagenta Therapeutics is a clinical-stage biotechnology company developing medicines to bring the curative power of immune system reset through stem cell transplant to more patients with autoimmune diseases, genetic diseases and blood cancers. Magenta is combining leadership in stem cell biology and biotherapeutics development with clinical and regulatory expertise, a unique business model and broad networks in the stem cell transplant world to revolutionize immune reset for more patients.\n\n\nMagenta is based in Cambridge, Mass. For more information, please visit www.magentatx.com.\n\n\nFollow Magenta on Twitter: @magentatx.\n\n\nForward-Looking Statement\n\n\nThis press release may contain forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as “may,” “will,” “could”, “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “seeks,” “endeavor,” “potential,” “continue” or the negative of such words or other similar expressions can be used to identify forward-looking statements. The express or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation risks set forth under the caption “Risk Factors” in Magenta’s Annual Report on Form 10-K filed on March 3, 2020, as updated by Magenta’s most...

More updates from Dianthus Therapeutics, Inc.